Genesis Therapeutics
Most recently Will was CBO at Generation Bio, where he helped drive corporate strategy initiatives including the company's ~$1B IPO. Previously he was CBO at Ignyta, where he was responsible for all aspects of commercial launch planning for the company's lead clinical asset, and was a key participant in the acquisition by Roche for ~$2B. Earlier in his career he led business development and marketing functions at Foundation Medicine, Halozyme and Neurocrine. He has an MBA from London Business School and a BA in Economics.
This person is not in any offices
Genesis Therapeutics
3 followers
Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D. In addition, Peppi Prasit, Ph.D. leads the Scientific Advisory Board and Leonard Bell, M.D., serves as Chair of the Board of Directors. Its team of technology trailblazers and proven drug developers are driving the discovery and development of novel small molecule drugs to treat patients suffering with severe and debilitating diseases. The company expects to develop drug candidates both internally and selectively in partnership with biopharmaceutical companies.